66 related articles for article (PubMed ID: 17707761)
1. [Sunitinib and hypothyroidism].
Cohen R; Bihan H; Uzzan B; des Guetz G; Krivitzky A
Ann Endocrinol (Paris); 2007 Oct; 68(5):332-6. PubMed ID: 17707761
[TBL] [Abstract][Full Text] [Related]
2. Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer.
Del Fabbro E; Dev R; Cabanillas ME; Busaidy NL; Rodriguez EC; Bruera E
J Chemother; 2012 Aug; 24(4):221-5. PubMed ID: 23040687
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib-induced autoimmune thyroiditis in a patient with metastatic renal cell carcinoma: a case report.
Babacan T; Sevinc A; Akarsu E; Balakan O
Chemotherapy; 2012; 58(2):142-5. PubMed ID: 22584361
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
6. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.
Mannavola D; Coco P; Vannucchi G; Bertuelli R; Carletto M; Casali PG; Beck-Peccoz P; Fugazzola L
J Clin Endocrinol Metab; 2007 Sep; 92(9):3531-4. PubMed ID: 17595247
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target.
Vetter ML; Kaul S; Iqbal N
Endocr Pract; 2008; 14(5):618-24. PubMed ID: 18753108
[TBL] [Abstract][Full Text] [Related]
8. The potential role of sunitinib in gastrointestinal cancers other than GIST.
Grávalos C; Grande E; Gasent JM
Crit Rev Oncol Hematol; 2010 Oct; 76(1):36-43. PubMed ID: 20133148
[TBL] [Abstract][Full Text] [Related]
9. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.
Desai J; Yassa L; Marqusee E; George S; Frates MC; Chen MH; Morgan JA; Dychter SS; Larsen PR; Demetri GD; Alexander EK
Ann Intern Med; 2006 Nov; 145(9):660-4. PubMed ID: 17088579
[TBL] [Abstract][Full Text] [Related]
10. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM
J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib: bridging present and future cancer treatment.
Grimaldi AM; Guida T; D'Attino R; Perrotta E; Otero M; Masala A; Cartenì G
Ann Oncol; 2007 Jun; 18 Suppl 6():vi31-4. PubMed ID: 17591828
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis for sunitinib efficacy and future clinical development.
Faivre S; Demetri G; Sargent W; Raymond E
Nat Rev Drug Discov; 2007 Sep; 6(9):734-45. PubMed ID: 17690708
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic application of sunitinib malate in the management of gastrointestinal stromal tumors.
MacIntyre J
Clin J Oncol Nurs; 2007 Apr; 11(2):237-41. PubMed ID: 17573273
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume.
Sakurai K; Fukazawa H; Arihara Z; Yoshida K
Tohoku J Exp Med; 2010 Sep; 222(1):39-44. PubMed ID: 20814176
[TBL] [Abstract][Full Text] [Related]
15. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.
Dawson SJ; Conus NM; Toner GC; Raleigh JM; Hicks RJ; McArthur G; Rischin D
Anticancer Drugs; 2008 Jun; 19(5):547-52. PubMed ID: 18418222
[TBL] [Abstract][Full Text] [Related]
16. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature.
Pasqualetti G; Ricci S; Dardano A; Ferdeghini M; Del Tacca M; Monzani F
Mini Rev Med Chem; 2011 Aug; 11(9):746-52. PubMed ID: 21707530
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib malate in the treatment of urothelial cancer.
Pons F; Bellmunt J
Expert Opin Investig Drugs; 2014 Jan; 23(1):115-24. PubMed ID: 24188025
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity.
Wong E; Rosen LS; Mulay M; Vanvugt A; Dinolfo M; Tomoda C; Sugawara M; Hershman JM
Thyroid; 2007 Apr; 17(4):351-5. PubMed ID: 17465866
[TBL] [Abstract][Full Text] [Related]
20. [Imatinib . Sunitinib].
Nishida T
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1196-200. PubMed ID: 17687201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
